カテゴリー： Market Monitor Global, 世界, 医療/バイオ

パーキンソン病治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Parkinsons Disease Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5875）

◆商品コード：MMG23JU5875
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月（※2025年版があります。お問い合わせください。）
◆ページ数：71
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Parkinsons Disease Drugs Market 調査レポートは次の情報を含め、グローバルにおけるのパーキンソン病治療薬市場規模と予測を収録しています。・世界のパーキンソン病治療薬市場：売上、2018年-2023年、2024年-2029年
・世界のパーキンソン病治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のパーキンソン病治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「臨床」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

パーキンソン病治療薬のグローバル主要企業は、Johnson & Johnson、 Gilead Sciences、 Pacira、 Sun Pharmaceutical、 Luye Pharma、 Sigma-Tau Group、 Fudan-Zhangjiang、 Teva Pharmaceutical、 CSPC、 Novartis、 Kingond Pharmなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、パーキンソン病治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のパーキンソン病治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界のパーキンソン病治療薬市場：タイプ別市場シェア、2022年
・臨床、実験

世界のパーキンソン病治療薬市場：用途別、2018年-2023年、2024年-2029年
世界のパーキンソン病治療薬市場：用途別市場シェア、2022年
・治療、予防

世界のパーキンソン病治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界のパーキンソン病治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるパーキンソン病治療薬のグローバル売上、2018年-2023年
・主要企業におけるパーキンソン病治療薬のグローバル売上シェア、2022年
・主要企業におけるパーキンソン病治療薬のグローバル販売量、2018年-2023年
・主要企業におけるパーキンソン病治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Johnson & Johnson、 Gilead Sciences、 Pacira、 Sun Pharmaceutical、 Luye Pharma、 Sigma-Tau Group、 Fudan-Zhangjiang、 Teva Pharmaceutical、 CSPC、 Novartis、 Kingond Pharm

*************************************************************

・調査・分析レポートの概要
パーキンソン病治療薬市場の定義
市場セグメント
世界のパーキンソン病治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のパーキンソン病治療薬市場規模
世界のパーキンソン病治療薬市場規模：2022年 VS 2029年
世界のパーキンソン病治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのパーキンソン病治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のパーキンソン病治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：臨床、実験
パーキンソン病治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：治療、予防
パーキンソン病治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別パーキンソン病治療薬市場規模 2022年と2029年
地域別パーキンソン病治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Johnson & Johnson、 Gilead Sciences、 Pacira、 Sun Pharmaceutical、 Luye Pharma、 Sigma-Tau Group、 Fudan-Zhangjiang、 Teva Pharmaceutical、 CSPC、 Novartis、 Kingond Pharm
...

Most people with Parkinson’s disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
This report aims to provide a comprehensive presentation of the global market for Parkinsons Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinsons Disease Drugs. This report contains market size and forecasts of Parkinsons Disease Drugs in global, including the following market information:
Global Parkinsons Disease Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Parkinsons Disease Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Parkinsons Disease Drugs companies in 2022 (%)
The global Parkinsons Disease Drugs market was valued at US$ 5651 million in 2022 and is projected to reach US$ 8459.7 million by 2029, at a CAGR of 5.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Parkinsons Disease Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Parkinsons Disease Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Parkinsons Disease Drugs Market Segment Percentages, by Type, 2022 (%)
Clinical
Experiment
Global Parkinsons Disease Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Parkinsons Disease Drugs Market Segment Percentages, by Application, 2022 (%)
Treament
Prevention
Global Parkinsons Disease Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Parkinsons Disease Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Parkinsons Disease Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Parkinsons Disease Drugs revenues share in global market, 2022 (%)
Key companies Parkinsons Disease Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Parkinsons Disease Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Outline of Major Chapters:
Chapter 1: Introduces the definition of Parkinsons Disease Drugs, market overview.
Chapter 2: Global Parkinsons Disease Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Parkinsons Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Parkinsons Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Parkinsons Disease Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Parkinsons Disease Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Parkinsons Disease Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Parkinsons Disease Drugs Overall Market Size
2.1 Global Parkinsons Disease Drugs Market Size: 2022 VS 2029
2.2 Global Parkinsons Disease Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Parkinsons Disease Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Parkinsons Disease Drugs Players in Global Market
3.2 Top Global Parkinsons Disease Drugs Companies Ranked by Revenue
3.3 Global Parkinsons Disease Drugs Revenue by Companies
3.4 Global Parkinsons Disease Drugs Sales by Companies
3.5 Global Parkinsons Disease Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Parkinsons Disease Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Parkinsons Disease Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Parkinsons Disease Drugs Players in Global Market
3.8.1 List of Global Tier 1 Parkinsons Disease Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Parkinsons Disease Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Parkinsons Disease Drugs Market Size Markets, 2022 & 2029
4.1.2 Clinical
4.1.3 Experiment
4.2 By Type – Global Parkinsons Disease Drugs Revenue & Forecasts
4.2.1 By Type – Global Parkinsons Disease Drugs Revenue, 2018-2023
4.2.2 By Type – Global Parkinsons Disease Drugs Revenue, 2024-2029
4.2.3 By Type – Global Parkinsons Disease Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Parkinsons Disease Drugs Sales & Forecasts
4.3.1 By Type – Global Parkinsons Disease Drugs Sales, 2018-2023
4.3.2 By Type – Global Parkinsons Disease Drugs Sales, 2024-2029
4.3.3 By Type – Global Parkinsons Disease Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Parkinsons Disease Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Parkinsons Disease Drugs Market Size, 2022 & 2029
5.1.2 Treament
5.1.3 Prevention
5.2 By Application – Global Parkinsons Disease Drugs Revenue & Forecasts
5.2.1 By Application – Global Parkinsons Disease Drugs Revenue, 2018-2023
5.2.2 By Application – Global Parkinsons Disease Drugs Revenue, 2024-2029
5.2.3 By Application – Global Parkinsons Disease Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Parkinsons Disease Drugs Sales & Forecasts
5.3.1 By Application – Global Parkinsons Disease Drugs Sales, 2018-2023
5.3.2 By Application – Global Parkinsons Disease Drugs Sales, 2024-2029
5.3.3 By Application – Global Parkinsons Disease Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Parkinsons Disease Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Parkinsons Disease Drugs Market Size, 2022 & 2029
6.2 By Region – Global Parkinsons Disease Drugs Revenue & Forecasts
6.2.1 By Region – Global Parkinsons Disease Drugs Revenue, 2018-2023
6.2.2 By Region – Global Parkinsons Disease Drugs Revenue, 2024-2029
6.2.3 By Region – Global Parkinsons Disease Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Parkinsons Disease Drugs Sales & Forecasts
6.3.1 By Region – Global Parkinsons Disease Drugs Sales, 2018-2023
6.3.2 By Region – Global Parkinsons Disease Drugs Sales, 2024-2029
6.3.3 By Region – Global Parkinsons Disease Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Parkinsons Disease Drugs Revenue, 2018-2029
6.4.2 By Country – North America Parkinsons Disease Drugs Sales, 2018-2029
6.4.3 US Parkinsons Disease Drugs Market Size, 2018-2029
6.4.4 Canada Parkinsons Disease Drugs Market Size, 2018-2029
6.4.5 Mexico Parkinsons Disease Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Parkinsons Disease Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Parkinsons Disease Drugs Sales, 2018-2029
6.5.3 Germany Parkinsons Disease Drugs Market Size, 2018-2029
6.5.4 France Parkinsons Disease Drugs Market Size, 2018-2029
6.5.5 U.K. Parkinsons Disease Drugs Market Size, 2018-2029
6.5.6 Italy Parkinsons Disease Drugs Market Size, 2018-2029
6.5.7 Russia Parkinsons Disease Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Parkinsons Disease Drugs Market Size, 2018-2029
6.5.9 Benelux Parkinsons Disease Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Parkinsons Disease Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Parkinsons Disease Drugs Sales, 2018-2029
6.6.3 China Parkinsons Disease Drugs Market Size, 2018-2029
6.6.4 Japan Parkinsons Disease Drugs Market Size, 2018-2029
6.6.5 South Korea Parkinsons Disease Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Parkinsons Disease Drugs Market Size, 2018-2029
6.6.7 India Parkinsons Disease Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Parkinsons Disease Drugs Revenue, 2018-2029
6.7.2 By Country – South America Parkinsons Disease Drugs Sales, 2018-2029
6.7.3 Brazil Parkinsons Disease Drugs Market Size, 2018-2029
6.7.4 Argentina Parkinsons Disease Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Parkinsons Disease Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Parkinsons Disease Drugs Sales, 2018-2029
6.8.3 Turkey Parkinsons Disease Drugs Market Size, 2018-2029
6.8.4 Israel Parkinsons Disease Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Parkinsons Disease Drugs Market Size, 2018-2029
6.8.6 UAE Parkinsons Disease Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Company Summary
7.1.2 Johnson & Johnson Business Overview
7.1.3 Johnson & Johnson Parkinsons Disease Drugs Major Product Offerings
7.1.4 Johnson & Johnson Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Johnson & Johnson Key News & Latest Developments
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Summary
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences Parkinsons Disease Drugs Major Product Offerings
7.2.4 Gilead Sciences Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Gilead Sciences Key News & Latest Developments
7.3 Pacira
7.3.1 Pacira Company Summary
7.3.2 Pacira Business Overview
7.3.3 Pacira Parkinsons Disease Drugs Major Product Offerings
7.3.4 Pacira Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Pacira Key News & Latest Developments
7.4 Sun Pharmaceutical
7.4.1 Sun Pharmaceutical Company Summary
7.4.2 Sun Pharmaceutical Business Overview
7.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Major Product Offerings
7.4.4 Sun Pharmaceutical Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Sun Pharmaceutical Key News & Latest Developments
7.5 Luye Pharma
7.5.1 Luye Pharma Company Summary
7.5.2 Luye Pharma Business Overview
7.5.3 Luye Pharma Parkinsons Disease Drugs Major Product Offerings
7.5.4 Luye Pharma Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Luye Pharma Key News & Latest Developments
7.6 Sigma-Tau Group
7.6.1 Sigma-Tau Group Company Summary
7.6.2 Sigma-Tau Group Business Overview
7.6.3 Sigma-Tau Group Parkinsons Disease Drugs Major Product Offerings
7.6.4 Sigma-Tau Group Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Sigma-Tau Group Key News & Latest Developments
7.7 Fudan-Zhangjiang
7.7.1 Fudan-Zhangjiang Company Summary
7.7.2 Fudan-Zhangjiang Business Overview
7.7.3 Fudan-Zhangjiang Parkinsons Disease Drugs Major Product Offerings
7.7.4 Fudan-Zhangjiang Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Fudan-Zhangjiang Key News & Latest Developments
7.8 Teva Pharmaceutical
7.8.1 Teva Pharmaceutical Company Summary
7.8.2 Teva Pharmaceutical Business Overview
7.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Major Product Offerings
7.8.4 Teva Pharmaceutical Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Teva Pharmaceutical Key News & Latest Developments
7.9 CSPC
7.9.1 CSPC Company Summary
7.9.2 CSPC Business Overview
7.9.3 CSPC Parkinsons Disease Drugs Major Product Offerings
7.9.4 CSPC Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.9.5 CSPC Key News & Latest Developments
7.10 Novartis
7.10.1 Novartis Company Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Parkinsons Disease Drugs Major Product Offerings
7.10.4 Novartis Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Novartis Key News & Latest Developments
7.11 Kingond Pharm
7.11.1 Kingond Pharm Company Summary
7.11.2 Kingond Pharm Parkinsons Disease Drugs Business Overview
7.11.3 Kingond Pharm Parkinsons Disease Drugs Major Product Offerings
7.11.4 Kingond Pharm Parkinsons Disease Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Kingond Pharm Key News & Latest Developments
8 Global Parkinsons Disease Drugs Production Capacity, Analysis
8.1 Global Parkinsons Disease Drugs Production Capacity, 2018-2029
8.2 Parkinsons Disease Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Parkinsons Disease Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Parkinsons Disease Drugs Supply Chain Analysis
10.1 Parkinsons Disease Drugs Industry Value Chain
10.2 Parkinsons Disease Drugs Upstream Market
10.3 Parkinsons Disease Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Parkinsons Disease Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Parkinsons Disease Drugs in Global Market
Table 2. Top Parkinsons Disease Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Parkinsons Disease Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Parkinsons Disease Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Parkinsons Disease Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Parkinsons Disease Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Parkinsons Disease Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Parkinsons Disease Drugs Product Type
Table 9. List of Global Tier 1 Parkinsons Disease Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Parkinsons Disease Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Parkinsons Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Parkinsons Disease Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Parkinsons Disease Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Parkinsons Disease Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Parkinsons Disease Drugs Sales (K Units), 2024-2029
Table 16. By Application – Global Parkinsons Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Parkinsons Disease Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Parkinsons Disease Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Parkinsons Disease Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Parkinsons Disease Drugs Sales (K Units), 2024-2029
Table 21. By Region – Global Parkinsons Disease Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Parkinsons Disease Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Parkinsons Disease Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Parkinsons Disease Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Parkinsons Disease Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Parkinsons Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Parkinsons Disease Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Parkinsons Disease Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Parkinsons Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Parkinsons Disease Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Parkinsons Disease Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Parkinsons Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Parkinsons Disease Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Parkinsons Disease Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Parkinsons Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Parkinsons Disease Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Parkinsons Disease Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Parkinsons Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Parkinsons Disease Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Parkinsons Disease Drugs Sales, (K Units), 2024-2029
Table 46. Johnson & Johnson Company Summary
Table 47. Johnson & Johnson Parkinsons Disease Drugs Product Offerings
Table 48. Johnson & Johnson Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Johnson & Johnson Key News & Latest Developments
Table 50. Gilead Sciences Company Summary
Table 51. Gilead Sciences Parkinsons Disease Drugs Product Offerings
Table 52. Gilead Sciences Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Gilead Sciences Key News & Latest Developments
Table 54. Pacira Company Summary
Table 55. Pacira Parkinsons Disease Drugs Product Offerings
Table 56. Pacira Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Pacira Key News & Latest Developments
Table 58. Sun Pharmaceutical Company Summary
Table 59. Sun Pharmaceutical Parkinsons Disease Drugs Product Offerings
Table 60. Sun Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Sun Pharmaceutical Key News & Latest Developments
Table 62. Luye Pharma Company Summary
Table 63. Luye Pharma Parkinsons Disease Drugs Product Offerings
Table 64. Luye Pharma Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Luye Pharma Key News & Latest Developments
Table 66. Sigma-Tau Group Company Summary
Table 67. Sigma-Tau Group Parkinsons Disease Drugs Product Offerings
Table 68. Sigma-Tau Group Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Sigma-Tau Group Key News & Latest Developments
Table 70. Fudan-Zhangjiang Company Summary
Table 71. Fudan-Zhangjiang Parkinsons Disease Drugs Product Offerings
Table 72. Fudan-Zhangjiang Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Fudan-Zhangjiang Key News & Latest Developments
Table 74. Teva Pharmaceutical Company Summary
Table 75. Teva Pharmaceutical Parkinsons Disease Drugs Product Offerings
Table 76. Teva Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Teva Pharmaceutical Key News & Latest Developments
Table 78. CSPC Company Summary
Table 79. CSPC Parkinsons Disease Drugs Product Offerings
Table 80. CSPC Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. CSPC Key News & Latest Developments
Table 82. Novartis Company Summary
Table 83. Novartis Parkinsons Disease Drugs Product Offerings
Table 84. Novartis Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Novartis Key News & Latest Developments
Table 86. Kingond Pharm Company Summary
Table 87. Kingond Pharm Parkinsons Disease Drugs Product Offerings
Table 88. Kingond Pharm Parkinsons Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. Kingond Pharm Key News & Latest Developments
Table 90. Parkinsons Disease Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 91. Global Parkinsons Disease Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Parkinsons Disease Drugs Production by Region, 2018-2023 (K Units)
Table 93. Global Parkinsons Disease Drugs Production by Region, 2024-2029 (K Units)
Table 94. Parkinsons Disease Drugs Market Opportunities & Trends in Global Market
Table 95. Parkinsons Disease Drugs Market Drivers in Global Market
Table 96. Parkinsons Disease Drugs Market Restraints in Global Market
Table 97. Parkinsons Disease Drugs Raw Materials
Table 98. Parkinsons Disease Drugs Raw Materials Suppliers in Global Market
Table 99. Typical Parkinsons Disease Drugs Downstream
Table 100. Parkinsons Disease Drugs Downstream Clients in Global Market
Table 101. Parkinsons Disease Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Parkinsons Disease Drugs Segment by Type in 2022
Figure 2. Parkinsons Disease Drugs Segment by Application in 2022
Figure 3. Global Parkinsons Disease Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Parkinsons Disease Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Parkinsons Disease Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Parkinsons Disease Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Parkinsons Disease Drugs Revenue in 2022
Figure 9. By Type - Global Parkinsons Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Parkinsons Disease Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Parkinsons Disease Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Parkinsons Disease Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Parkinsons Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Parkinsons Disease Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Parkinsons Disease Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Parkinsons Disease Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Parkinsons Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Parkinsons Disease Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Parkinsons Disease Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Parkinsons Disease Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Parkinsons Disease Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Parkinsons Disease Drugs Sales Market Share, 2018-2029
Figure 23. US Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Parkinsons Disease Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Parkinsons Disease Drugs Sales Market Share, 2018-2029
Figure 28. Germany Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Parkinsons Disease Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Parkinsons Disease Drugs Sales Market Share, 2018-2029
Figure 37. China Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Parkinsons Disease Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Parkinsons Disease Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Parkinsons Disease Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Parkinsons Disease Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Parkinsons Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Parkinsons Disease Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Parkinsons Disease Drugs by Region, 2022 VS 2029
Figure 54. Parkinsons Disease Drugs Industry Value Chain
Figure 55. Marketing Channels

※参考情報

パーキンソン病は神経変性疾患の一種で、中枢神経系のドーパミン神経細胞が減少することによって引き起こされます。この疾患は主に運動機能に影響を及ぼし、震え、筋剛直、動作の遅れ（徐動）、姿勢の不安定性などの症状が見られます。現在のところ、この病気を完全に治す方法は確立されていませんが、症状を軽減し、患者の生活の質（QOL）を向上させるための治療薬が多く開発されています。

パーキンソン病治療薬は、大きく分けてドーパミンの作用を補強する薬と、その他のメカニズムを介して症状を軽減する薬があります。最も広く使用されている治療薬は、レボドパ（L-DOPA）です。この薬は体内でドーパミンに変換され、ドーパミンの不足を補うことによって症状を緩和します。レボドパは通常、カルビドパと併用されます。カルビドパはレボドパが脳に到達する前に分解されるのを防ぎ、効果的な用量を維持する役割を果たします。

レボドパの他にも、ドーパミンアゴニストと呼ばれる薬剤群があります。これらは直接ドーパミン受容体に作用してドーパミンの効果を模倣するもので、プラミペキソールやロピニロールが含まれます。ドーパミンアゴニストは、レボドパに比べて初期の段階で使われることが多く、副作用が少ない点が特徴です。ただし、長期使用による副作用のリスクも考慮しなければなりません。

また、MAO-B阻害剤やCOMT阻害剤もパーキンソン病の治療に用いられます。MAO-B阻害剤はドーパミンの分解を抑えることで、脳内のドーパミン濃度を維持する役割があります。エネルカポン（Entacapone）がCOMT阻害剤の一つで、レボドパの効果を持続させるために使用されます。

さらに、抗コリン薬もパーキンソン病の治療に利用されることがあります。これは主に震えを緩和するために使用され、アトロピンやトロピカミドといった薬剤があります。抗コリン薬は特に若年性のパーキンソン病患者において効果的ですが、高齢者では副作用が出やすいため注意が必要です。

加えて、最近ではパーキンソン病に対する新たな治療法として、神経成長因子や遺伝子治療、さらには細胞治療などの研究も進められています。これらのアプローチは、病気の進行を抑制したり、神経細胞の再生を促進したりすることを目的としています。特に細胞治療では、患者自身の細胞や幹細胞を利用して、損なわれた神経細胞を修復する試みが行われています。

医療の進展に伴い、パーキンソン病の治療薬も多様化していますが、これらの薬剤はすべてが完璧であるわけではありません。副作用や耐性の問題も存在し、治療にあたる医師は患者にとって最も効果的かつ安全な治療法を選択する必要があります。また、パーキンソン病の治療は薬物療法だけでなく、リハビリテーションや食事療法、心理的サポートが重要であることも忘れてはなりません。

このように、パーキンソン病の治療薬は多岐にわたり、各々が異なるメカニズムで作用しています。今後も新たな研究や治療法の開発が続き、パーキンソン病患者の生活の質の向上が図られることが期待されます。治療薬は症状の管理に不可欠ですが、患者一人ひとりの症状やライフスタイルに応じたアプローチが重要です。このような多角的なアプローチにより、パーキンソン病に苦しむ多くの患者がより豊かな生活を送れるようになることを願っています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ パーキンソン病治療薬の世界市場見通し2023年-2029年(Parkinsons Disease Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

パーキンソン病治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp